Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSC) Share-based Compensation (2020 - 2025)

Historic Share-based Compensation for Ensysce Biosciences (ENSC) over the last 6 years, with Q3 2025 value amounting to $45858.0.

  • Ensysce Biosciences' Share-based Compensation rose 12028.05% to $45858.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $182896.0, marking a year-over-year decrease of 7422.22%. This contributed to the annual value of $110723.0 for FY2024, which is 8740.58% down from last year.
  • Per Ensysce Biosciences' latest filing, its Share-based Compensation stood at $45858.0 for Q3 2025, which was up 12028.05% from $90638.0 recorded in Q2 2025.
  • Ensysce Biosciences' Share-based Compensation's 5-year high stood at $1.7 million during Q1 2022, with a 5-year trough of -$1.0 in Q3 2022.
  • For the 5-year period, Ensysce Biosciences' Share-based Compensation averaged around $167048.6, with its median value being $34790.0 (2021).
  • In the last 5 years, Ensysce Biosciences' Share-based Compensation crashed by 10000.4% in 2022 and then surged by 2096443333.33% in 2023.
  • Ensysce Biosciences' Share-based Compensation (Quarter) stood at $16738.0 in 2021, then crashed by 99.98% to $3.0 in 2022, then surged by 20964433.33% to $628936.0 in 2023, then tumbled by 95.21% to $30149.0 in 2024, then soared by 52.1% to $45858.0 in 2025.
  • Its Share-based Compensation was $45858.0 in Q3 2025, compared to $90638.0 in Q2 2025 and $16251.0 in Q1 2025.